Screening Medications for the Treatment of Cannabis Use Disorder.

[1]  G. Bedi,et al.  Oral Cannabidiol does not Alter the Subjective, Reinforcing or Cardiovascular Effects of Smoked Cannabis , 2016, Neuropsychopharmacology.

[2]  J. Rehm,et al.  Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings. , 2016, Drug and alcohol dependence.

[3]  M. Pavlicova,et al.  Dronabinol and lofexidine for cannabis use disorder: A randomized, double-blind, placebo-controlled trial. , 2016, Drug and alcohol dependence.

[4]  R. Murray,et al.  The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: A placebo-controlled, double-blind, crossover pilot trial , 2016, Journal of psychopharmacology.

[5]  J. Rehm,et al.  Effects of fixed or self-titrated dosages of Sativex on cannabis users , 2015 .

[6]  J. Thome,et al.  Is There a Place for Off-Label Pharmacotherapy in Cannabis Use Disorder? A Review on Efficacy and Safety. , 2015, Current pharmaceutical design.

[7]  J. Copeland,et al.  Cannabinoid replacement therapy (CRT): Nabiximols (Sativex) as a novel treatment for cannabis withdrawal , 2015, Clinical pharmacology and therapeutics.

[8]  L. Panlilio,et al.  Cannabinoid abuse and addiction: Clinical and preclinical findings , 2015, Clinical pharmacology and therapeutics.

[9]  G. Bedi,et al.  Naltrexone Maintenance Decreases Cannabis Self-Administration and Subjective Effects in Daily Cannabis Smokers , 2015, Neuropsychopharmacology.

[10]  S. Nikas,et al.  Cannabinoid withdrawal in mice: inverse agonist vs neutral antagonist , 2015, Psychopharmacology.

[11]  R. Bertorelli,et al.  Methylphenidate modifies the motion of the circadian clock Lamotrigine in mood disorders and cocaine dependence Cortical glutamate in postpartum depression Effects of Fatty Acid Amide Hydrolase ( FAAH ) Inhibitors in Non-Human Primate Models of Nicotine Reward and Relapse , 2015 .

[12]  V. Di Marzo,et al.  Are cannabidiol and Δ9‐tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review , 2015, British journal of pharmacology.

[13]  W. Hall.  What has research over the past two decades revealed about the adverse health effects of recreational cannabis use? , 2015, Addiction.

[14]  P. Cowen,et al.  Neural Effects of Cannabinoid CB1 Neutral Antagonist Tetrahydrocannabivarin on Food Reward and Aversion in Healthy Volunteers , 2015, The international journal of neuropsychopharmacology.

[15]  R. Ali,et al.  Pharmacotherapies for cannabis dependence. , 2014, The Cochrane database of systematic reviews.

[16]  Udi E. Ghitza,et al.  Achieving cannabis cessation -- evaluating N-acetylcysteine treatment (ACCENT): design and implementation of a multi-site, randomized controlled study in the National Institute on Drug Abuse Clinical Trials Network. , 2014, Contemporary clinical trials.

[17]  C. Lançon,et al.  Acute and long-term effects of cannabis use: a review. , 2014, Current pharmaceutical design.

[18]  J. Copeland,et al.  Cannabis smoking and respiratory health: Consideration of the literature , 2014, Respirology.

[19]  A. Winstock,et al.  Lithium carbonate in the management of cannabis withdrawal: a randomized placebo-controlled trial in an inpatient setting , 2014, Psychopharmacology.

[20]  Benjamin J. Whalley,et al.  Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders , 2014, Epilepsia.

[21]  S. Goldberg,et al.  Differential Effects of Presynaptic versus Postsynaptic Adenosine A2A Receptor Blockade on Δ9-Tetrahydrocannabinol (THC) Self-Administration in Squirrel Monkeys , 2014, The Journal of Neuroscience.

[22]  Alexander Strashny,et al.  Comparing and Evaluating Substance Use Treatment Utilization Estimates from the National Survey on Drug Use and Health and Other Data Sources , 2014 .

[23]  M. Berk,et al.  Systematic review of N-acetylcysteine in the treatment of addictions. , 2014, Revista brasileira de psiquiatria.

[24]  J. Wiley,et al.  Evaluation of WIN 55,212-2 self-administration in rats as a potential cannabinoid abuse liability model , 2014, Pharmacology Biochemistry and Behavior.

[25]  M. Haney,et al.  Novel Pharmacologic Approaches to Treating Cannabis Use Disorder , 2014, Current Addiction Reports.

[26]  I. McGregor,et al.  Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial. , 2014, JAMA psychiatry.

[27]  W. Fantegrossi,et al.  Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ(9)-THC: mechanism underlying greater toxicity? , 2014, Life sciences.

[28]  P. Piazza,et al.  Pregnenolone Can Protect the Brain from Cannabis Intoxication , 2014, Science.

[29]  A. Weinstein,et al.  Treatment of cannabis dependence using escitalopram in combination with cognitive-behavior therapy: a double-blind placebo-controlled study , 2014, The American journal of drug and alcohol abuse.

[30]  L. Dušek,et al.  Enhanced self-administration of the CB1 receptor agonist WIN55,212-2 in olfactory bulbectomized rats: evaluation of possible serotonergic and dopaminergic underlying mechanisms , 2013, Front. Pharmacol..

[31]  J. Hirvonen,et al.  Cannabis withdrawal in chronic, frequent cannabis smokers during sustained abstinence within a closed residential environment. , 2013, The American journal on addictions.

[32]  B. Sadek,et al.  Effects of cannabidiol on the function of α7-nicotinic acetylcholine receptors. , 2013, European journal of pharmacology.

[33]  S. Vosburg,et al.  A human laboratory study investigating the effects of quetiapine on marijuana withdrawal and relapse in daily marijuana smokers , 2013, Addiction biology.

[34]  M. Pistis,et al.  Reducing cannabinoid abuse and preventing relapse by enhancing endogenous brain levels of kynurenic acid , 2013, Nature Neuroscience.

[35]  G. Bedi,et al.  Subjective, cognitive and cardiovascular dose‐effect profile of nabilone and dronabinol in marijuana smokers , 2013, Addiction biology.

[36]  M. Haney,et al.  Marijuana's dose-dependent effects in daily marijuana smokers. , 2013, Experimental and clinical psychopharmacology.

[37]  G. Bedi,et al.  Nabilone Decreases Marijuana Withdrawal and a Laboratory Measure of Marijuana Relapse , 2013, Neuropsychopharmacology.

[38]  Janet B W Williams,et al.  Diagnostic and Statistical Manual of Mental Disorders , 2013 .

[39]  Donna J. Calu,et al.  The reinstatement model of drug relapse: recent neurobiological findings, emerging research topics, and translational research , 2013, Psychopharmacology.

[40]  M. Stitzer,et al.  The dose effects of short-term dronabinol (oral THC) maintenance in daily cannabis users. , 2013, Drug and alcohol dependence.

[41]  D. D’Souza,et al.  Naltrexone does not attenuate the effects of intravenous Δ9-tetrahydrocannabinol in healthy humans. , 2012, The international journal of neuropsychopharmacology.

[42]  Shanlin Fu,et al.  Quantifying the Clinical Significance of Cannabis Withdrawal , 2012, PloS one.

[43]  T. Smart,et al.  An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee , 2012, PAIN®.

[44]  K. Brady,et al.  A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents. , 2012, The American journal of psychiatry.

[45]  E. Oleson,et al.  A brain on cannabinoids: the role of dopamine release in reward seeking. , 2012, Cold Spring Harbor perspectives in medicine.

[46]  G. Jay,et al.  Assessment of the pharmacology and tolerability of PF-04457845, an irreversible inhibitor of fatty acid amide hydrolase-1, in healthy subjects. , 2012, British journal of clinical pharmacology.

[47]  M. Hellmich,et al.  Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia , 2012, Translational Psychiatry.

[48]  S. Quello,et al.  A Proof-of-Concept Randomized Controlled Study of Gabapentin: Effects on Cannabis Use, Withdrawal and Executive Function Deficits in Cannabis-Dependent Adults , 2012, Neuropsychopharmacology.

[49]  L. McMahon,et al.  The fatty acid amide hydrolase inhibitor URB 597: interactions with anandamide in rhesus monkeys , 2011, British journal of pharmacology.

[50]  J. Crippa,et al.  Safety and side effects of cannabidiol, a Cannabis sativa constituent. , 2011, Current drug safety.

[51]  R. Franco,et al.  Reinforcing and neurochemical effects of cannabinoid CB1 receptor agonists, but not cocaine, are altered by an adenosine A2A receptor antagonist , 2011, Addiction biology.

[52]  M. Pavlicova,et al.  Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial. , 2011, Drug and alcohol dependence.

[53]  I. McGregor,et al.  Cannabidiol potentiates Δ9-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats , 2011, Psychopharmacology.

[54]  S. Goldberg,et al.  The Endogenous Cannabinoid 2-Arachidonoylglycerol Is Intravenously Self-Administered by Squirrel Monkeys , 2011, The Journal of Neuroscience.

[55]  P. Sexton,et al.  Allosteric modulation of G protein-coupled receptors: A pharmacological perspective , 2011, Neuropharmacology.

[56]  P. McGuire,et al.  Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report , 2011, Journal of psychopharmacology.

[57]  Stephen P. H. Alexander,et al.  International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands: Beyond CB1 and CB2 , 2010, Pharmacological Reviews.

[58]  E. Hermans,et al.  Functionally selective cannabinoid receptor signalling: therapeutic implications and opportunities. , 2010, Biochemical pharmacology.

[59]  S. Vosburg,et al.  Effects of baclofen and mirtazapine on a laboratory model of marijuana withdrawal and relapse , 2010, Psychopharmacology.

[60]  L. Panlilio,et al.  Animal models of cannabinoid reward , 2010, British journal of pharmacology.

[61]  M. Haney,et al.  Opioid antagonism enhances marijuana's effects in heavy marijuana smokers , 2010, Psychopharmacology.

[62]  L. Panlilio,et al.  Effects of cannabinoid receptor antagonists on maintenance and reinstatement of methamphetamine self-administration in rhesus monkeys. , 2010, European journal of pharmacology.

[63]  L. McMahon,et al.  Rimonabant-Induced Δ9-Tetrahydrocannabinol Withdrawal in Rhesus Monkeys: Discriminative Stimulus Effects and Other Withdrawal Signs , 2010, Journal of Pharmacology and Experimental Therapeutics.

[64]  K. Gray,et al.  N-acetylcysteine (NAC) in young marijuana users: an open-label pilot study. , 2010, The American journal on addictions.

[65]  P. Maccioni,et al.  Blockade of the cannabinoid CB1 receptor and alcohol dependence: preclinical evidence and preliminary clinical data. , 2010, CNS & neurological disorders drug targets.

[66]  R. Capasso,et al.  Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. , 2009, Trends in pharmacological sciences.

[67]  K. Antoniou,et al.  Behavioural and dopaminergic alterations induced by a low dose of WIN 55,212-2 in a conditioned place preference procedure. , 2009, Life sciences.

[68]  G. Heyman.  Addiction: A Disorder of Choice , 2009 .

[69]  S. Goldberg,et al.  The future of endocannabinoid-oriented clinical research after CB1 antagonists , 2009, Psychopharmacology.

[70]  A. Makriyannis,et al.  Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis , 2009 .

[71]  Á. Díaz,et al.  Altered CB1 receptor‐signaling in prefrontal cortex from an animal model of depression is reversed by chronic fluoxetine , 2009, Journal of neurochemistry.

[72]  K. Carpenter,et al.  A preliminary trial: double-blind comparison of nefazodone, bupropion-SR, and placebo in the treatment of cannabis dependence. , 2009, The American journal on addictions.

[73]  L. Panlilio,et al.  Blockade of THC-Seeking Behavior and Relapse in Monkeys by the Cannabinoid CB1-Receptor Antagonist Rimonabant , 2008, Neuropsychopharmacology.

[74]  S. Passik,et al.  Challenges in Using Opioids to Treat Pain in Persons With Substance Use Disorders , 2008, Addiction science & clinical practice.

[75]  A. Makriyannis,et al.  Some effects of CB1 antagonists with inverse agonist and neutral biochemical properties , 2008, Physiology & Behavior.

[76]  S. Vosburg,et al.  Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse , 2008, Psychopharmacology.

[77]  L. Panlilio,et al.  Self-administration of drugs in animals and humans as a model and an investigative tool. , 2007, Addiction.

[78]  A. Budney,et al.  Marijuana Dependence and Its Treatment , 2007, Addiction science & clinical practice.

[79]  S. Hjorth,et al.  The orphan receptor GPR55 is a novel cannabinoid receptor , 2007, British journal of pharmacology.

[80]  R. Ross.  Allosterism and cannabinoid CB(1) receptors: the shape of things to come. , 2007, Trends in pharmacological sciences.

[81]  S. Heishman,et al.  Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users , 2007, Psychopharmacology.

[82]  G. Nomikos,et al.  Lack of evidence for appetitive effects of Δ9-tetrahydrocannabinol in the intracranial self-stimulation and conditioned place preference procedures in rodents , 2007, Behavioural pharmacology.

[83]  M. Haney.  Opioid Antagonism of Cannabinoid Effects: Differences between Marijuana Smokers and Nonmarijuana Smokers , 2007, Neuropsychopharmacology.

[84]  S. Goldberg,et al.  Nicotinic α7 Receptors as a New Target for Treatment of Cannabis Abuse , 2007, The Journal of Neuroscience.

[85]  J. Hughes,et al.  Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms. , 2007, Drug and alcohol dependence.

[86]  L. Panlilio,et al.  Using drug-discrimination techniques to study the abuse-related effects of psychoactive drugs in rats , 2006, Nature Protocols.

[87]  R. Maldonado,et al.  Involvement of κ/Dynorphin System in WIN 55,212-2 Self-Administration in Mice , 2006, Neuropsychopharmacology.

[88]  S. Heishman,et al.  The cannabinoid CB1 receptor antagonist rimonabant attenuates the hypotensive effect of smoked marijuana in male smokers. , 2006, American heart journal.

[89]  A. Schoffelmeer,et al.  Cannabinoid CB1 receptors control conditioned drug seeking. , 2005, Trends in pharmacological sciences.

[90]  S. Goldberg,et al.  The Endogenous Cannabinoid Anandamide and Its Synthetic Analog R(+)-Methanandamide Are Intravenously Self-Administered by Squirrel Monkeys , 2005, The Journal of Neuroscience.

[91]  C. Stanger,et al.  Cannabis withdrawal in adolescent treatment seekers. , 2005, Drug and alcohol dependence.

[92]  S. Goldberg,et al.  Cannabinoid CB1 Receptor Antagonists as Promising New Medications for Drug Dependence , 2005, Journal of Pharmacology and Experimental Therapeutics.

[93]  Thomas Babor,et al.  The Cannabis Youth Treatment (CYT) Study: main findings from two randomized trials. , 2004, Journal of substance abuse treatment.

[94]  K. Carroll,et al.  Brief treatments for cannabis dependence: findings from a randomized multisite trial. , 2004, Journal of consulting and clinical psychology.

[95]  E. Nunes,et al.  Pharmacotherapy for marijuana dependence: a double-blind, placebo-controlled pilot study of divalproex sodium. , 2004, The American journal on addictions.

[96]  G. Cossu,et al.  Cannabinoids and reward: interactions with the opioid system. , 2004, Critical reviews in neurobiology.

[97]  S. Vosburg,et al.  Marijuana Withdrawal in Humans: Effects of Oral THC or Divalproex , 2004, Neuropsychopharmacology.

[98]  S. Goldberg,et al.  The opioid antagonist naltrexone reduces the reinforcing effects of Δ9-tetrahydrocannabinol (THC) in squirrel monkeys , 2004, Psychopharmacology.

[99]  L. Degenhardt,et al.  Exploring the association between cannabis use and depression. , 2003, Addiction.

[100]  S. Goldberg,et al.  Self-administration of Δ9-tetrahydrocannabinol (THC) by drug naive squirrel monkeys , 2003, Psychopharmacology.

[101]  M. Haney,et al.  Interaction between naltrexone and oral THC in heavy marijuana smokers , 2003, Psychopharmacology.

[102]  G. Riedel,et al.  Effects of Δ9-THC and WIN-55,212-2 on place preference in the water maze in rats , 2003, Psychopharmacology.

[103]  Raphael Mechoulam,et al.  Cannabidiol: An Overview of Some Pharmacological Aspects , 2002, Journal of clinical pharmacology.

[104]  Richard W. Foltin,et al.  Comparison of smoked marijuana and oral Δ9-tetrahydrocannabinol in humans , 2002, Psychopharmacology.

[105]  C. Hart,et al.  Effects of oral THC maintenance on smoked marijuana self-administration. , 2002, Drug and alcohol dependence.

[106]  T. Kirkham,et al.  Reversal of Δ9-THC hyperphagia by SR141716 and naloxone but not dexfenfluramine , 2002, Pharmacology Biochemistry and Behavior.

[107]  D. K. Hannesson,et al.  Prevention of Cannabinoid Withdrawal Syndrome by Lithium: Involvement of Oxytocinergic Neuronal Activation , 2001, The Journal of Neuroscience.

[108]  R. Stephens,et al.  A randomized controlled trial of brief cognitive-behavioral interventions for cannabis use disorder. , 2001, Journal of substance abuse treatment.

[109]  G. Cossu,et al.  Intravenous self-administration of the cannabinoid CB1 receptor agonist WIN 55,212-2 in rats , 2001, Psychopharmacology.

[110]  A. Lichtman,et al.  Precipitated cannabinoid withdrawal is reversed by Δ9-tetrahydrocannabinol or clonidine , 2001, Pharmacology Biochemistry and Behavior.

[111]  S. Heishman,et al.  Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. , 2001, Archives of general psychiatry.

[112]  S. Goldberg,et al.  Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys , 2000, Nature Neuroscience.

[113]  R. Stephens,et al.  Comparison of extended versus brief treatments for marijuana use. , 2000, Journal of consulting and clinical psychology.

[114]  J. Cheer,et al.  Cannabinoid receptors and reward in the rat: a conditioned place preference study , 2000, Psychopharmacology.

[115]  J. Hughes,et al.  Marijuana withdrawal among adults seeking treatment for marijuana dependence. , 1999, Addiction.

[116]  Richard W. Foltin,et al.  Abstinence symptoms following smoked marijuana in humans , 1999, Psychopharmacology.

[117]  M. Haney,et al.  Abstinence symptoms following oral THC administration to humans , 1999, Psychopharmacology.

[118]  G. Gessa,et al.  Self-administration of the cannabinoid receptor agonist WIN 55,212-2 in drug-naive mice , 1998, Neuroscience.

[119]  M. Haney,et al.  The effects of a monetary alternative on marijuana self-administration , 1997, Behavioural Pharmacology.

[120]  M. Haney,et al.  Behavioral contingencies modulate alprazolam self‐administration by humans , 1997, Behavioural pharmacology.

[121]  J. Lowe,et al.  Antagonism of the discriminative stimulus effects of delta 9-tetrahydrocannabinol in rats and rhesus monkeys. , 1995, The Journal of pharmacology and experimental therapeutics.

[122]  Katz Jl,et al.  The use of second-order schedules to study the influence of environmental stimuli on drug-seeking behavior. , 1988 .

[123]  R. Herning,et al.  Clinical Relevance of Cannabis Tolerance and Dependence , 1981, Journal of clinical pharmacology.

[124]  N. Benowitz,et al.  CLINICAL STUDIES OF CANNABIS TOLERANCE AND DEPENDENCE * , 1976, Annals of the New York Academy of Sciences.